| | |

New Pill Could Make Mesothelioma Diagnosis Easier, More Accurate

A pill that makes cancer cells glow under infrared light may have the capacity to improve the diagnosis of malignant mesothelioma.

So far, the pill, being developed by researchers at the University of MIchigan with funding from the NIH, has only been tested on breast cancer tumors in mice.

But it was so effective at exposing hidden clusters of cancer cells, that the research team expects it to be useful in the diagnosis of other cancers, too. That could eventually include mesothelioma.

The Urgent Need for Earlier Mesothelioma Diagnosis

Mesothelioma, a fast-growing cancer caused by asbestos exposure, is diagnosed in about 2,500 new patients in the US each year. About 2,000 of them have pleural mesothelioma, the most common type.

Since mesothelioma symptoms don’t typically occur until many years after asbestos exposure, mesothelioma is almost always diagnosed at an advanced stage. This drastically reduces the likelihood of treatment success and mesothelioma survival rates are among the worst of any cancer.  

But, if mesothelioma could be identified earlier, potentially even before symptoms develop, it is much more likely to be treatable. The same is true of many types of cancer.

 

Pill Finds “Hidden” Cancer Cells

The possibility of earlier, more accurate cancer diagnosis is the idea behind the new molecular imaging pill.

The pill contains two parts. One part is based on an experimental cancer treatment drug that failed to fight cancer in clinical trials but was successful at transporting the treatment agent into the bloodstream, which is a big part of the battle in getting drugs where they need to go.

The second part contains an infrared dye that targets particular molecules found on cancer cells and in the blood vessels that feed them. In most types of molecular imaging studies, the dye is injected. But a small percentage of people can have a serious reaction to this dye.

Putting the delivery agent and the dye together creates a pill that effectively delivers dye to cancer cells without the potential side effects of injection. In the new study of the diagnostic pill, none of the breast cancer mice had a reaction to the dye.

Pill Could Expose Mesothelioma Tumors

Infrared light has the ability to penetrate tissue. When it hits the dye inside of the cancer cells, tumors “light up”.

The hope is that the method would make it possible to diagnose breast cancer and other types of malignancies without the use of ionizing radiation, which poses its own risks.

According to University of Michigan assistant professor of chemical engineering and biomedical engineering, Greg Thurber, who led the research team, “This approach should be adaptable to other molecular targets and diseases for use as a new class of screening agents.”

Currently, mesothelioma diagnosis is done through a combination of imaging scans, blood and fluid tests for biomarkers, biopsies, and careful history.

The new report appears in a recent issue of the journal Molecular Pharmaceutics.

Source:

Bhatnagar, S, et al, “Oral Administration and Detection of a Near-Infrared Molecular Imaging Agent in an Orthotopic Mouse Model for Breast Cancer Screening”, April 26, 2018, Molecular Pharmaceutics

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • |

    Mesothelioma Blood Test May Be Possible

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…

  • | |

    New Mesothelioma Drug Kills Cancer Stem Cells

    Citing “significant enthusiasm within the mesothelioma community”, the manufacturers of a promising new mesothelioma drug say they have begun a major test of the drug in patients. Massachusetts-based Verastem, Inc. focuses on drugs that fight cancer by attacking the stem cells that give rise to them. Earlier this summer, the FDA granted orphan drug status to their stem cell inhibitor, defactinib, for the treatment of mesothelioma. The designation, which is reserved for drugs that fight the rarest of diseases, helps pave the way for testing and faster approval, depending on the results of clinical trials. “Development of a drug that preferentially kills cancer stem cells is a promising approach, as many standard-of-care treatments have been shown to either have no…